In preclinical melanoma models, navitoclax administration resulted in the clearance of TIS tumor cells, dampened SASP production, and enhanced infiltration of functional CD8+ T cells, ultimately improving response to anti‐PD‐1 therapy [116]. The gene discussed is CD8A; the disease is neoplasm.